•
•
Sources
Story Timeline
•Latest version
AstraZeneca Raises Annual Profit Outlook on Strong Drug Demand, Reports Q3 Core Profit of $1.73, Enters Anti-Obesity Market with $2 Billion Deal
AstraZeneca Raises Profit Outlook, Plans $2 Billion Anti-Obesity Drug Boost, Q3 Profit Per Share $1.73, China's Eccogene Deal
•Original version
AstraZeneca Boosts Anti-Obesity Pipeline with $2 Billion Deal with China's Eccogene for Experimental Oral Drug
